Elevation Oncology, Inc. (ELEV) 2023年年度报告「NASDAQ」.pdf

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2023ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、OF 1934For The Transition Period FromToCommission file number:001-40523ELEVATION ONCOLOGY,INC.(Exact name of registrant as specified in its charter)Delaware84-1771427(State of Other Jurisdiction of incorporation or Organization)(I.R.S.Employer Identification No.)101 Federal Street,Suite 1900,Boston,

3、Massachusetts02110(Address of principal executive offices)(Zip code)Registrants telephone number,including area code:(716)371-1125Securities registered pursuant to Section 12(b)of the Act:Name Of Each ExchangeTitle of Each ClassTrading Symbol(s)On Which RegisteredCommon stock,par value$0.0001 per sh

4、areELEVThe Nasdaq Stock Market LLCSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursua

5、nt to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to fi

6、le such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.0405 of this chapter)duringthe pr